Maximizing Outcomes in Relapsed/Refractory Multiple Myeloma: Tailoring Bispecific Antibody Approaches
Medical experts explore tailored treatment strategies for patients with relapsed/refractory multiple myeloma using bispecific antibodies, featuring expert insights and a patient profile portrayal to guide clinical decision-making.
EP. 1: John’s Journey with R/R MM
68-year-old male construction worker with a long history of multiple myeloma, managing multiple lines of treatment including BCMA-directed CAR T therapy, alongside a history of hypertension, respiratory infections, and type 2 diabetes, now receiving talquetamab.
EP. 2: MonumenTAL: Key Efficacy Outcomes
Dr Nadeem to summarize the clinical evidence supporting talquetamab use in relapsed/refractory multiple myeloma, including key efficacy outcomes from the monumenTAL trials.
EP. 3: Implications of Talquetamab on the Current Treatment Landscape for R/R MM
Dr Mohan and Dr Mann discuss the current therapeutic landscape for relapsed/refractory multiple myeloma (R/R MM), alternative treatment strategies, and the real-world performance, advantages, and challenges of incorporating talquetamab into treatment protocols.
EP. 4: Bispecifics in R/R MM: Selecting the Best Bispecific and Optimal Sequencing Strategies
Dr Mohan asks Dr Nadeem about the selection process among bispecific antibodies, the factors influencing decision-making, and the use of talquetamab, teclistamab, or elranatamab in specific patient subgroups, followed by a discussion with Dr Mann on next therapeutic steps if a patient experiences disease progression on talquetamab.
EP. 6: MagnestisMM: Key Efficacy Data and its Clinical Implications
In this segment, Dr. Mohan asks Dr. Mann to summarize the key efficacy data from the MagnestisMM trials evaluating the use of elranatamab in relapsed/refractory multiple myeloma (R/R MM).
